Literature DB >> 19375664

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

K Ray Chaudhuri1, Anthony H V Schapira.   

Abstract

Several studies, including work from the Parkinson's disease (PD) non-motor group and others, have established that the non-motor symptoms of PD are common, occur across all stages of PD, are under-reported, and are a key determinant of quality of life. Research suggests that the non-motor symptoms of the disease are frequently unrecognised by clinicians and remain untreated. Even when identified, there is a common perception that many of these symptoms are untreatable. The role of dopaminergic drugs in treating the various non-motor problems of PD, although clinically recognised, has received little attention. In this Review, we investigate the dopaminergic basis of the range of non-motor symptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sleep behaviour disorder), and erectile dysfunction. We discuss the evidence that these symptoms are treatable, at least in part, with various dopaminergic strategies and, where relevant, we also refer to the use of deep-brain stimulation of appropriate targets in the brain. This Review provides a comprehensive overview of the management of this challenging aspect of PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19375664     DOI: 10.1016/S1474-4422(09)70068-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  430 in total

Review 1.  [Deep brain stimulation for Parkinson's disease].

Authors:  J Herzog; G Deuschl
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 2.  Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

Authors:  Yoland Smith; Thomas Wichmann; Stewart A Factor; Mahlon R DeLong
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Modern treatment in Parkinson's disease, a personal approach.

Authors:  Heinz Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2015-08-21       Impact factor: 3.575

Review 4.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

5.  Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.

Authors:  Thomas M Kaiser; Zackery W Dentmon; Christopher E Dalloul; Savita K Sharma; Dennis C Liotta
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

Review 6.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 7.  Pathophysiology of somatosensory abnormalities in Parkinson disease.

Authors:  Antonella Conte; Nashaba Khan; Giovanni Defazio; John C Rothwell; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

8.  Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion.

Authors:  Anton Ilango; Andrew J Kesner; Kristine L Keller; Garret D Stuber; Antonello Bonci; Satoshi Ikemoto
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

Review 9.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

Review 10.  Parkinsonian syndromes.

Authors:  David R Williams; Irene Litvan
Journal:  Continuum (Minneap Minn)       Date:  2013-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.